Regeneron is a leading biotechnology company that develops medicines for people with serious diseases, and has substantial clinical trial and regulatory activity in the EU. The Biotech Act's CTR and SPC proposals address real barriers to that work, but impact depends on consistent implementation across Member States and alignment of the EHDS Regulation secondary use provisions with CTR/EMA Policy 0070.
RPI
Regeneron Pharmaceuticals Inc.
Company · United States · EU Transparency Register 045767293922-02
1
position filed
in the 326 files tracked
1
legislative file
of 326 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #827 by legislative files engaged — a count of participation, not a measure of influence.
0.2
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2024
in the register since
Declares membership of
- EUCOPE
- Regeneron is corporate member of the Transform Alliance, the European Haemophilia Consortium and the European Federat…
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Head office
- Tarrytown, United states
- EU office
- Dublin
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Regeneron in PolicySpeak: request access →
Work at Regeneron Pharmaceuticals Inc.? so we know who speaks for it.
Their record over time
Regeneron Pharmaceuticals Inc. filed 1 position on 3 Aug 2026, across 1 of the 326 legislative files tracked here.
What they argued
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Is this your organization?
Everything on this page comes from Regeneron Pharmaceuticals Inc.’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.